Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 4/20 | 0.54 |
| ▸ | SNCA | P37840 | 4/20 | 0.50 |
| ▸ | BCHE | P06276 | 7/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926804 | 1.00 | NOX1 (0.54) | NOX1SNCABCHEACHEL3MBTL1 | |
| SCHEMBL8223437 | 0.91 | NOX1 (0.46) | NOX1SNCABCHEACHEL3MBTL1 | |
| SCHEMBL18408661 | 0.89 | MAPK1 (0.55) | NOX1SNCABCHEACHEL3MBTL1 | |
| SCHEMBL396463 | 0.85 | BCHE (0.61) | NOX1SNCABCHEACHEKMT2A | |
| SCHEMBL10847578 | 0.85 | NOX1 (0.53) | NOX1SNCAL3MBTL1MEN1KMT2A | |
| SCHEMBL29850631 | 0.83 | NOX1 (0.50) | NOX1SNCABCHEKDM4E | |
| SCHEMBL1207987 | 0.83 | NOX1 (0.50) | NOX1SNCABCHEKDM4E | |
| SCHEMBL1828804 | 0.82 | SNCA (0.44) | NOX1SNCABCHEACHEL3MBTL1 | |
| SCHEMBL12955933 | 0.80 | MEN1 (0.63) | SNCABCHEACHEL3MBTL1MEN1 | |
| SCHEMBL14142982 | 0.79 | BCHE (0.61) | NOX1SNCABCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115580-A1 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS | WISTA LABORATORIES LTD. (SG) | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115580-A1 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS | MB, TPMT, HBB | NOX1 1655/4885SNCA 173/4885BCHE 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.